Affimed N.V. (AFMD)
| Market Cap | 965.30M |
| Revenue (ttm) | 34.59M |
| Net Income (ttm) | -50.45M |
| Shares Out | 118.95M |
| EPS (ttm) | -0.60 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 11 |
| Last Price | $8.15 |
| Previous Close | $8.20 |
| Change ($) | -0.05 |
| Change (%) | -0.61% |
| Day's Open | 8.20 |
| Day's Range | 8.03 - 8.34 |
| Day's Volume | 547,656 |
| 52-Week Range | 2.90 - 11.74 |
Heidelberg, Germany, May 26, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its...
Heidelberg, Germany, May 20, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its...
Affimed NV (NASDAQ: AFMD) has announced the publication of in vitro and in vivo research of its lead innate cell engager (ICE), AFM13 (CD16A/CD30), combined with healthy donor-derived Natural killer (NK...
This biotech stock has already produced some big returns this year.
AFM13 in combination with natural killer (NK) cells demonstrated improved tumor recognition and enhanced tumor cell killing in vitro and in vivo.
Affimed (AFMD) has moved higher as of late, but there could definitely be trouble on the horizon for this company
The company's latest quarterly update was less than impressive.
Heidelberg, Germany, April 15, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financi...
Heidelberg, Germany, April 12, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announces pre-clinical...
A 100% response rate is impressive, albeit in just four patients.
Affimed NV (NASDAQ: AFMD) has announced initial clinical data from an investigator-sponsored study evaluating cord blood-derived natural killer (cbNK) cells pre-complexed with Affimed's innate cell enga...
Heidelberg, Germany, April 8, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it...
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
Heidelberg, Germany and Santa Ana, Calif., March 31, 2021 - Affimed N.V. (NASDAQ: AFMD), a clinical-stage immuno-oncology company, and NKMax America Inc., a clinical stage biotech company, announced tod...
Heidelberg, Germany, March 10, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that p...
Following the Independent Review Committee's assessment, Affimed NV (NASDAQ: AFMD) will continue enrollment in Phase 2 REDIRECT trial evaluating AFM13 as a monotherapy for relapsed or refractory CD30-po...
Heidelberg, Germany, March 10, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today its de...
Steven Cohen (Trades, Portfolio), the billionaire investor who leads Point72 Asset Management, disclosed earlier this week his firm upped its stake in Affimed NV (NASDAQ:AFMD) by 190.73%.
Affimed N.V. (NASDAQ: AFMD) has entered into a clinical research collaboration with Roche Holding AG (OTC: RHHBF) to explore the combination of Affimed's AFM24 with Roche's atezolizumab (Tecentriq) for ...
Heidelberg, Germany, February 3, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that...
Heidelberg, Germany, January 15, 2021 – Affimed N.V. (“Affimed” or the “Company”) (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight...
Affimed (AFMD) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Heidelberg, Germany, January 13, 2021 – Affimed N.V. (“Affimed” or the “Company”) (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight...
Heidelberg, Germany, January 12, 2021 – Affimed N.V. (“Affimed” or the “Company”) (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight...
Heidelberg, Germany, January 11, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that...
Heidelberg, Germany, January 11, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that...
Heidelberg, Germany, January 7, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an up...
Affimed continues to amass a stockpile of partnerships and collaborations that amplifies the risk-reward profile for an AFMD investment. As a result, I am looking to accumulate a larger position. I prov...
Heidelberg, Germany, December 7, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the ...
The phase 1b study showed a complete response (CR) rate of 46% (objective response rate [ORR] of 88%) at the recommended dose level in patients with relapsed/refractory (R/R) Hodgkin lymphoma, whereas ...
Affimed N.V. (AFMD) CEO Adi Hoess on Q3 2020 Results - Earnings Call Transcript
Affimed N.V.'s (AFMD) CEO Adi Hoess On Q3 2020 Results - Quick Version Earnings Call Transcript
Affimed N.V. (AFMD) delivered earnings and revenue surprises of 33.33% and 94.55%, respectively, for the quarter ended September 2020.
Shares of Affimed (NASDAQ:AFMD) rose 11.3% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 57.89% over the past year to ($0.08), which beat th...
Heidelberg, Germany, Novembe r 10 , 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported fi...
Affimed to grant license to AFM32 with options for additional ICE® molecules directed against targets not included in Affimed's current pipeline
Virtual data presentation at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting on Wednesday, November 11, 2020
Exclusive collaboration to assess feasibility and activity of pre-manufactured, co-vialed, cryopreserved, off-the-shelf NK cell combination therapeutics targeting EGFR and additional targets
Heidelberg, Germany, November 4, 2020 – Affimed N.V., (NASDAQ: AFMD) a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, announced today th...
Heidelberg, Germany, November 4, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that...
Heidelberg, Germany, November 3, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that...
Heidelberg, Germany, and Santa Ana, California, October 20, 2020 – Affimed N.V. (NASDAQ: AFMD) and NKMax America Inc., both clinical stage biotech companies focused on harnessing the power of the body's...
Heidelberg, Germany, October 14, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that...
Pilsen, Czech Republic, October 6, 2020 - AbCheck s.r.o., a leader in providing antibody drug discovery, engineering and optimization services to the biotech and pharmaceutical industry, today announced...
Heidelberg, Germany, October 6, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that ...
Heidelberg, Germany, September 29, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced th...
Heidelberg, Germany, September 2, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced th...
Affimed N.V. (AFMD) CEO Adi Hoess on Q2 2020 Results - Earnings Call Transcript
Affimed N.V. (AFMD) delivered earnings and revenue surprises of -50.00% and -52.45%, respectively, for the quarter ended June 2020.
About AFMD
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, which has completed Phase II clinical study of CD30-positive T-cell lymphoma, and hodgkin lymphoma (HL), as well as is in Phase II clinical trials for peripheral T-cell lymphoma, and transformed mycosis fungoides; that is in Phase I clinical study in combination with adoptive NK cells for CD30-postive lymphomas; and has completed Phase Ib clinical s... [Read more...]
| Industry Biotechnology | IPO Date Sep 12, 2014 |
| Stock Exchange NASDAQ | Ticker Symbol AFMD |
Financial Performance
In 2020, Affimed N.V.'s revenue was 28.36 million, an increase of 32.58% compared to the previous year's 21.39 million. Losses were -41.37 million, 27.8% more than in 2019.
Analyst Forecasts
According to 5 analysts, the average rating for Affimed N.V. stock is "Strong Buy." The 12-month stock price forecast is 15.41, which is an increase of 89.08% from the latest price.